Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
China channel feed
China's Tasly Biopharma turns a development partner into an investor as it preps Hong Kong IPO
8 years ago
Pharma
7 things you need to know now about raising biotech cash in China (Part 1)
8 years ago
Financing
Another IPO frenzy? Two US biotechs head to Hong Kong for a public market debut
8 years ago
Financing
Hong Kong exchange picks up steam with two biotech IPOs from Innovent, MicuRx
8 years ago
Financing
Sanofi gets serious in China with plans to hire 300 for $76M R&D site in Chengdu
8 years ago
R&D
Forget the biotech mega-round. Try the $200M-plus China 'ultra' on for size
8 years ago
Financing
C-Bridge hands Nuance Biotech $35M, opening doors to more China licensing deals
8 years ago
Financing
R&D
Latest ranking of top research institutions show China coming on strong — with significant implications for biotech
8 years ago
R&D
With an AstraZeneca cancer drug in one hand, $37M in the other, Shanghai's Alpha Bio zooms into a PhII study
8 years ago
Financing
Startups
High-profile Chinese investor Vincent Cheung plays a lead role in raising $100M round for a Boston start-up
8 years ago
Financing
A functional HIV cure? We have a long way to go, but Hong Kong investigators find a spotlight for their preclinical antibody
8 years ago
Discovery
Bristol-Myers wins the frenzied race to a first approval for a PD-1/L1 checkpoint in China as regulators hustle up a quick OK
8 years ago
Pharma
AI team at Insilico gets some major league backing from China as Alex Zhavoronkov builds global network
8 years ago
Financing
AI
Sound familiar? China/US biotech hybrid lands rights to cancer drugs, cash and a team of development vets to launch Oncologie
8 years ago
Financing
Startups
Manufacturing experts at Hangzhou Just Biotherapeutics bank $35M for stealthy R&D in China and the US
8 years ago
Financing
Eyeing NDA for its diabetes drug, Hua Medicine knocks at HKEX's door with an IPO application
8 years ago
Financing
Prepping a drug launch, Zai Lab poaches AstraZeneca’s top cancer drug sales exec in China
8 years ago
People
With competition on its heels, Blueprint takes three cancer drugs to China
8 years ago
Pharma
After sinking $300M into SF fund last year, Hong Kong conglomerate launches $100M arm in Shanghai
8 years ago
Financing
CRI report tracks explosive growth of cell therapies in the global pipeline, as China researchers muscle toward the front
8 years ago
Cell/Gene Tx
Grail hauls in monster $300M round from Chinese investors amid rumors about Hong Kong IPO
8 years ago
Financing
China's CStone bags $260M Series B for ambitious I/O work, expanding its list of marquee investors
8 years ago
Financing
Set to be the first pre-revenue biotech to list in Hong Kong, Ascletis lays out priorities in IPO application
8 years ago
Financing
Ahead of Hong Kong listing changes, WuXi preps for a biotech boom with a new R&D center in Shanghai
8 years ago
R&D
Pharma
First page
Previous page
24
25
26
27
28
29
30
Next page
Last page